IL10 and neoplasm: We have previously shown that JNJ28 (5 mg kg−1) increased IL-10 and decreased IFNγ levels in 4T1 tumours, this was accompanied by an increase in the percentage of Tregs in TDLN.23 In agreement with these results, the treatment with JNJ77 reduced the percentage of tumour-infiltrating CD4+ T cells and Tregs in TDLN, similar to the response observed in H4R-KO mice.